Understanding Quality of Life After Cytoreductive Surgery and HIPEC for Peritoneal Metastases
- 2 days ago
- 3 min read
Zhu Y, Hanna N, Boutros C, Alexander HR Jr. Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases. J Gastrointest Oncol. 2013 Mar;4(1):62-71. doi: 10.3978/j.issn.2078-6891.2012.053. PMID: 23450068; PMCID: PMC3562622.
What Was This Study About?
Peritoneal metastases occur when cancer spreads to the lining of the abdomen (the peritoneum). This can happen with cancers such as colorectal, appendiceal, gastric (stomach), ovarian cancers, and peritoneal mesothelioma.
Historically, patients with peritoneal metastases had very limited treatment options and poor survival. Researchers reviewed published studies to better understand how a treatment called cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) affects both survival and quality of life.
What Are CRS and HIPEC?
Cytoreductive surgery (CRS) is a complex operation that removes as much visible cancer as possible from the abdomen.
HIPEC is a treatment given during surgery in which heated chemotherapy is circulated throughout the abdominal cavity to destroy remaining cancer cells that may be too small to see.
The goal of CRS and HIPEC is to improve survival and, in some patients, potentially achieve long-term disease control.
What Did Researchers Find?
Survival Can Improve in Selected Patients
The review found that carefully selected patients who undergo CRS and HIPEC may live significantly longer than patients treated with standard therapies alone.
For example:
Patients with colorectal cancer that has spread to the peritoneum experienced longer survival after CRS and HIPEC compared with chemotherapy alone.
Patients with appendiceal cancers and peritoneal mesothelioma often had some of the best outcomes, with some surviving for many years after treatment.
Outcomes for stomach cancer were generally less favorable, although some patients still benefited.
Results varied depending on:
Cancer type
Extent of disease
Whether surgeons were able to remove all visible tumors
What Are the Risks?
CRS and HIPEC are major procedures and can involve:
Long operations
Extended hospital stays
Significant recovery time
Potential complications include:
Bleeding
Infection
Blood clots
Bowel leaks or bowel obstruction
Low blood counts
Kidney or liver side effects related to chemotherapy
However, researchers noted that complication rates and treatment-related deaths have decreased over time because of better patient selection, surgical experience, and improvements in postoperative care.
What About Quality of Life?
Because CRS and HIPEC are intensive treatments, researchers wanted to know whether patients felt better or worse after recovery.
Several studies found that:
Quality of life often declines during the first few months after surgery.
Physical functioning, energy levels, and daily activities may be temporarily affected.
Most patients gradually recover and return to their baseline level of functioning within 3 to 6 months.
Many patients report improved quality of life by 6 to 12 months after treatment.
Pain often improves over time.
Emotional well-being may improve as patients recover.
Mental Health Matters
Some studies found that depression and emotional distress were common before and after treatment.
Researchers reported that:
About one-quarter to one-half of patients experienced symptoms of depression at different time points.
Emotional support and ongoing mental health care may be important parts of recovery.
Long-Term Recovery
Among long-term survivors:
Many reported good or excellent health years after treatment.
Most were able to perform normal daily activities.
Some patients continued to experience fatigue, pain, or limitations in social activities.
Overall, many survivors were able to return to meaningful and active lives following recovery.
What Does This Mean for Patients?
CRS and HIPEC may offer meaningful benefits for selected patients with cancers that have spread to the lining of the abdomen.
While the treatment is complex and recovery can be challenging, research suggests that:
Many patients regain their quality of life within months after surgery.
Pain and symptoms may improve.
Survival can be significantly longer for some patients compared with standard treatments alone.
Careful evaluation by an experienced multidisciplinary team is important to determine whether CRS and HIPEC are appropriate.
Key Takeaway
For appropriately selected patients with peritoneal metastases, CRS and HIPEC can provide both longer survival and a return to good quality of life after recovery. Although treatment carries risks and requires a substantial recovery period, many patients report meaningful improvements in daily functioning and well-being within the first year after surgery.
